Patents by Inventor Mark L. Ragains

Mark L. Ragains has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
    Publication number: 20160368933
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: April 22, 2016
    Publication date: December 22, 2016
    Inventors: Xiaoqi CHEN, Kang DAI, Jason DUQUETTE, Michael W. GRIBBLE, JR., Justin N. HUARD, Kathleen S. KEEGAN, Zhihong LI, Sarah E. LIVELY, Lawrence R. MCGEE, Mark L. RAGAINS, Xianghong WANG, Margaret F. WEIDNER, Jian ZHANG
  • Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
    Patent number: 9359355
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 7, 2016
    Assignee: AMGEN INC.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
    Publication number: 20140163052
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: November 25, 2013
    Publication date: June 12, 2014
    Applicant: AMGEN INC.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
    Patent number: 8623885
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 7, 2014
    Assignee: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
    Publication number: 20120244110
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 27, 2012
    Applicant: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang